Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Niagen
2. Nicotinamide Ribonucleoside
3. Nicotinamide Ribose
4. Nicotinamide-beta-riboside
5. Pyridinium, 3-(aminocarbonyl)-1-beta-d-ribofuranosyl-
6. Ribosylnicotinamide
7. Srt 647
8. Srt-647
9. Srt647
10. Truniagen
1. 1341-23-7
2. Nicotinamide Ribose
3. N-ribosylnicotinamide
4. Nicotinamide-beta-riboside
5. Nicotinamide Ribonucleoside
6. Ribosylnicotinamide
7. 3-carbamoyl-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium
8. 1-(beta-d-ribofuranosyl)nicotinamide
9. 0i8h2m0l7n
10. Chebi:15927
11. 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
12. Pyridinium, 3-(aminocarbonyl)-1-beta-d-ribofuranosyl-
13. 3-carbamoyl-1-beta-d-ribofuranosylpyridinium
14. Niagen
15. Truniagen
16. Srt647
17. Srt 647
18. Srt-647
19. N-ribosyl-nicotinamide
20. Beta-nicotinamide D-riboside
21. Unii-0i8h2m0l7n
22. N-ribosyl-nicotinamide New
23. Schembl938611
24. Chembl438497
25. Dtxsid501010039
26. Zinc4096036
27. 1-(beta-d Ribofuranosyl)nicotinamide
28. 1-b-d-ribosyl-3-pyridinecarboxamide
29. Nicotinamide Riboside [who-dd]
30. 1-beta-d-ribosyl-3-pyridinecarboxamide
31. Am84366
32. Db14933
33. 1-beta-delta-ribosyl-3-pyridinecarboxamide
34. Hy-123033
35. Cs-0080934
36. C03150
37. 3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium
38. 3-(aminocarbonyl)-1beta-d-ribofuranosylpyridinium
39. 3-(aminocarbonyl)-1-beta-d-ribofuranosyl-pyridinium
40. Beta-nicotinamide Ribose;beta-nicotinamide Riboside
41. Q3334152
42. 3-(aminocarbonyl)-1-beta-delta-ribofuranosyl-pyridinium
43. Pyridinium, 3-(aminocarbonyl)-1-.beta.-d-ribofuranosyl-
44. 3-carbamoyl-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1$l^{5}-pyridin-1-ylium
Molecular Weight | 255.25 g/mol |
---|---|
Molecular Formula | C11H15N2O5+ |
XLogP3 | -1.8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 255.09809658 g/mol |
Monoisotopic Mass | 255.09809658 g/mol |
Topological Polar Surface Area | 117 Ų |
Heavy Atom Count | 18 |
Formal Charge | 1 |
Complexity | 314 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : Hubei Aoks Bio-tech is located in Hubei province of China.We specialized in the research, development, production and trade of organic intermediates, pharmaceutical intermediates ,...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Neurology Brand Name: Niagen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2023
Details:
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Brand Name: Tru Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Details:
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Brand Name: Tru Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 27, 2022
Details:
The cross-border distribution strategy allows for Tru Niagen® (nicotinamide riboside) 300mg 30 count bottles, Tru Niagen® 300mg 90 count bottles and Tru Niagen® 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Brand Name: Tru Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: MyPharma2Go Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 01, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : MyPharma2Go Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Details : The cross-border distribution strategy allows for Tru Niagen® (nicotinamide riboside) 300mg 30 count bottles, Tru Niagen® 300mg 90 count bottles and Tru Niagen® 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 01, 2022
Details:
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Brand Name: Tru Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: ChromaDex, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 10, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : ChromaDex, Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2022
Details:
Tru Niagen Immune, is a combination of ingredient Niagen (nicotinamide riboside), and Theracurmin (curcumin) is first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Brand Name: Tru Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
Details : Tru Niagen Immune, is a combination of ingredient Niagen (nicotinamide riboside), and Theracurmin (curcumin) is first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells.
Brand Name : Tru Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2022
Details:
A newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen (nicotinamide riboside) ingredient and other nicotinamide adenine dinucleotide (NAD) precursors.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Brand Name: Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen (nicotinamide riboside) ingredient and other nicotinamide adenine dinucleotide (NAD) precursors.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Details:
Results of phase I clinical trial for Niagen, showed that NR supplementation significantly increased cerebral nicotinamide adenine dinucleotide levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in patients with PD.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Neurology Brand Name: Niagen
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results of phase I clinical trial for Niagen, showed that NR supplementation significantly increased cerebral nicotinamide adenine dinucleotide levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in p...
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2022
Details:
Niagen® replenishes levels of NAD+, supports healthy cellular metabolism, and helps mitochondria function more eciently to promote healthy aging at the cellular level.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Ophthalmology Brand Name: Niagen
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Niagen® replenishes levels of NAD+, supports healthy cellular metabolism, and helps mitochondria function more eciently to promote healthy aging at the cellular level.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2022
Details:
ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Brand Name: Niagen
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Designs for Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 20, 2022
Lead Product(s) : Nicotinamide Riboside
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Designs for Health
Deal Size : Undisclosed
Deal Type : Agreement
ChromaDex and Designs for Health Partner for New Product Development on Niagen
Details : ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 20, 2022
Market Place
Reply
24 Oct 2018
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?